SG11202101396SA - Transcriptional regulatory element and its use in enhancing the expression of heterologous protein - Google Patents
Transcriptional regulatory element and its use in enhancing the expression of heterologous proteinInfo
- Publication number
- SG11202101396SA SG11202101396SA SG11202101396SA SG11202101396SA SG11202101396SA SG 11202101396S A SG11202101396S A SG 11202101396SA SG 11202101396S A SG11202101396S A SG 11202101396SA SG 11202101396S A SG11202101396S A SG 11202101396SA SG 11202101396S A SG11202101396S A SG 11202101396SA
- Authority
- SG
- Singapore
- Prior art keywords
- enhancing
- expression
- regulatory element
- transcriptional regulatory
- heterologous protein
- Prior art date
Links
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/100467 WO2020034097A1 (en) | 2018-08-14 | 2018-08-14 | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
PCT/CN2019/100549 WO2020034986A1 (en) | 2018-08-14 | 2019-08-14 | Transcriptional regulatory element and its use in enhancing the expression of heterologous protein |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101396SA true SG11202101396SA (en) | 2021-03-30 |
Family
ID=69524632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101396SA SG11202101396SA (en) | 2018-08-14 | 2019-08-14 | Transcriptional regulatory element and its use in enhancing the expression of heterologous protein |
Country Status (7)
Country | Link |
---|---|
US (2) | US11254952B2 (zh) |
EP (1) | EP3837368B1 (zh) |
JP (1) | JP7018163B2 (zh) |
KR (1) | KR102370150B1 (zh) |
CN (2) | CN116555264A (zh) |
SG (1) | SG11202101396SA (zh) |
WO (2) | WO2020034097A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4107272A2 (en) | 2020-02-19 | 2022-12-28 | Wuxi Biologics Ireland Limited | Enhanced expression system and methods of use thereof |
US20230323391A1 (en) * | 2020-06-30 | 2023-10-12 | The University Court Of The University Of Edinburgh | Transgene expression system |
CN115584394A (zh) * | 2022-10-17 | 2023-01-10 | 昆明理工大学 | 一种从废旧锂离子电池中浸出锂镍钴锰的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3346010A1 (en) | 2003-06-24 | 2018-07-11 | Genzyme Corporation | Novel beta-actin and rps21 promoters and uses thereof |
JP4407635B2 (ja) | 2003-07-22 | 2010-02-03 | 株式会社大真空 | 音叉型振動片、音叉型振動子、および音叉型振動片の製造方法 |
US7790446B2 (en) | 2005-02-11 | 2010-09-07 | Kosagen Cell Factory Oü | Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products |
US8377653B2 (en) | 2005-02-11 | 2013-02-19 | Icosagen Cell Factory Oü | Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays |
US20080124760A1 (en) * | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
JP4525863B1 (ja) | 2009-06-05 | 2010-08-18 | 東洋紡績株式会社 | 高生産性細胞の樹立のための発現ベクター及び高生産性細胞 |
AU2010297011A1 (en) * | 2009-09-18 | 2012-04-12 | Selexis S.A. | Products and methods for enhanced transgene expression and processing |
JP5940554B2 (ja) * | 2010-12-09 | 2016-06-29 | アンスティテュ・パストゥールInstitut Pasteur | 高収量の組換えタンパク質発現を得るためのmgmtに基づく方法 |
ES2540753T3 (es) * | 2012-09-24 | 2015-07-13 | Lonza Biologics Plc. | Vectores de expresión que comprenden secuencias quiméricas de promotor y amplificador de citomegalovirus |
CN103834686B (zh) * | 2012-11-23 | 2016-05-25 | 上海药明生物技术有限公司 | 高效克隆筛选表达载体、其制备方法及用途 |
KR101599138B1 (ko) | 2014-06-17 | 2016-03-03 | 한국생명공학연구원 | 재조합 단백질 발현 증진을 위한 유전자 절편을 포함하는 벡터 및 이의 용도 |
CN106459999B (zh) * | 2014-06-18 | 2024-10-11 | 新加坡科技研究局 | 用于高水平表达的新型启动子 |
KR20160068558A (ko) | 2014-12-05 | 2016-06-15 | 삼성바이오에피스 주식회사 | 마우스 cmv 프로모터를 포함하는 융합 폴리뉴클레오타이드 및 이를 이용한 목적 폴리펩타이드의 생산 방법 |
CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
CN105255895B (zh) * | 2015-11-06 | 2018-01-02 | 爱博环球生物技术有限公司 | 用于真核细胞系的提高蛋白表达水平的mar转录调控元件及其表达系统 |
AR108295A1 (es) | 2016-04-20 | 2018-08-08 | Regeneron Pharma | Composiciones y métodos para preparar anticuerpos basados en el uso de un locus mejorador de expresión |
DK3328887T3 (da) | 2016-09-19 | 2021-09-20 | I Mab Biopharma Hangzhou Co Ltd | Anti-GM-CSF antistoffer og anvendelser deraf |
CN106987559A (zh) | 2017-03-22 | 2017-07-28 | 上海药明生物技术有限公司 | 一种重组chok1细胞株的构建方法及其应用 |
-
2018
- 2018-08-14 WO PCT/CN2018/100467 patent/WO2020034097A1/en active Application Filing
-
2019
- 2019-08-14 JP JP2021507820A patent/JP7018163B2/ja active Active
- 2019-08-14 KR KR1020217007752A patent/KR102370150B1/ko active IP Right Grant
- 2019-08-14 US US17/268,360 patent/US11254952B2/en active Active
- 2019-08-14 CN CN202310511931.7A patent/CN116555264A/zh active Pending
- 2019-08-14 SG SG11202101396SA patent/SG11202101396SA/en unknown
- 2019-08-14 EP EP19850474.8A patent/EP3837368B1/en active Active
- 2019-08-14 WO PCT/CN2019/100549 patent/WO2020034986A1/en unknown
- 2019-08-14 CN CN201980052283.5A patent/CN113039272B/zh active Active
-
2022
- 2022-01-10 US US17/572,262 patent/US20220127637A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210254100A1 (en) | 2021-08-19 |
CN116555264A (zh) | 2023-08-08 |
US20220127637A1 (en) | 2022-04-28 |
KR102370150B1 (ko) | 2022-03-03 |
JP2021525548A (ja) | 2021-09-27 |
WO2020034097A1 (en) | 2020-02-20 |
EP3837368B1 (en) | 2023-01-11 |
CN113039272B (zh) | 2023-05-30 |
WO2020034986A1 (en) | 2020-02-20 |
US11254952B2 (en) | 2022-02-22 |
EP3837368A4 (en) | 2021-12-01 |
CN113039272A (zh) | 2021-06-25 |
JP7018163B2 (ja) | 2022-02-09 |
EP3837368A1 (en) | 2021-06-23 |
KR20210046706A (ko) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268206A (en) | Antibodies directed against bcma and their use | |
ZA202006904B (en) | Anti-il-4r antibody and use thereof | |
SG11202100746WA (en) | Anti-tigit antibody and use thereof | |
IL304393A (en) | Mva or mvadele3l recombinants expressing human flt3l and their use as immunotherapeutic agents against solid tumors | |
IL265489B (en) | Recombinant binding proteins and their uses | |
DK3508580T3 (da) | Ny promotor og anvendelse deraf | |
ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
SG10201912690PA (en) | Protein cage-stabilized pickering emulsions and the use thereof | |
ZA201900209B (en) | Novel natural protein and application thereof | |
SG11202009787VA (en) | Modified mitochondria and use thereof | |
IL282708A (en) | Anti-tim-3 antibodies and their use | |
SG11202104912SA (en) | Fusion protein and use thereof | |
HUE050121T2 (hu) | Új tripszin izoformák és alkalmazásuk | |
IL282707A (en) | Anti-tim-3 antibodies and their use | |
SG11202011000SA (en) | Taste and flavor-modifier proteins | |
SG11202101396SA (en) | Transcriptional regulatory element and its use in enhancing the expression of heterologous protein | |
ZA202100092B (en) | Modified cas9 protein and use thereof | |
ZA201906248B (en) | Anti-ceacam1 antibody and use thereof | |
GB201819200D0 (en) | Polypeptide and uses thereof | |
IL282527A (en) | 5-Azaindazole history and their use | |
IL282526A (en) | 5-Azaindazole history and their use | |
GB2600592B (en) | Polypeptide and use thereof | |
PT3757295T (pt) | Recipiente e utilização do mesmo | |
ZA201805811B (en) | Hypersensitive response elicitor-derived peptides and use thereof | |
GB201803363D0 (en) | New materials and uses thereof |